长链非编码RNA CCAT1的过表达是乳腺癌患者预后不良的一种新生物标志物。
Overexpression of long non-coding RNA CCAT1 is a novel biomarker of poor prognosis in patients with breast cancer.
作者信息
Zhang Xin-Feng, Liu Ting, Li Yang, Li Su
机构信息
Department of Breast Surgery, Liaoning Cancer Hospital and Institute Shenyang 110042, China.
Department of Radiology, First Affiliated Hospital, China Medical University Shenyang 110001, China.
出版信息
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9440-5. eCollection 2015.
INTRODUCTION
Recent studies have demonstrated that lncRNA CCAT1 was increased in many types of cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance and prognostic value of lncRNA CCAT1 in breast cancer (BC) haven't been investigated.
METHODS
Expression levels of lncRNA CCAT1 in 92 pairs of BC cancer tissues and adjacent normal tissues were detected by quantitative real-time PCR. In order to determine its prognostic value, overall survival and progression-free survival were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis.
RESULTS
Expression levels of lncRNA CCAT1 in BC tissues were significantly higher than those in adjacent normal tissues. High expression of lncRNA CCAT1 was associated with differentiation grade, TNM stage, and lymph node metastases. Kaplan-Meier analysis with the log-rank test indicated that high expression of lncRNA CCAT1 had a decreased overall survival and progression-free survival. Multivariable analysis was further identified high expression of lncRNA CCAT1 as an independent prognosis factor for overall survival and progression-free survival.
CONCLUSIONS
Our findings provided that the expression of lncRNA CCAT1 was up-regulated in BC and associated with overall survival as well as progression-free survival, suggesting that lncRNA CCAT1 could be a potential prognostic biomarker for BC progression.
引言
最近的研究表明，lncRNA CCAT1在多种癌症中表达增加，并参与了与致癌作用相关的各种细胞过程。然而，lncRNA CCAT1在乳腺癌（BC）中的临床意义和预后价值尚未得到研究。
方法
采用定量实时PCR检测92对BC癌组织及癌旁正常组织中lncRNA CCAT1的表达水平。为了确定其预后价值，采用Kaplan-Meier法评估总生存期和无进展生存期，并采用Cox比例风险分析进行多因素分析。
结果
BC组织中lncRNA CCAT1的表达水平显著高于癌旁正常组织。lncRNA CCAT1的高表达与分化程度、TNM分期及淋巴结转移相关。采用对数秩检验的Kaplan-Meier分析表明，lncRNA CCAT1的高表达使总生存期和无进展生存期降低。多因素分析进一步确定lncRNA CCAT1的高表达是总生存期和无进展生存期的独立预后因素。
结论
我们的研究结果表明，lncRNA CCAT1在BC中表达上调，并与总生存期和无进展生存期相关，提示lncRNA CCAT1可能是BC进展的潜在预后生物标志物。
Zotero 插件